<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.35213.005</object-id><label>Table 1.</label><caption><title>Summary of the density model estimation of efficacy against prevalence and parasite density for the transmission blocking (TBV) and pre-erythrocytic (PEV) antibodies that were administered either alone or together to reduce malaria parasites in mice.</title><p>The interaction between the two antibodies are measured using the ratio of observed estimates for combination treatments compared to the expected efficacy were vaccine antibodies acting independently using the simulated posterior draws from the density model (<xref ref-type="bibr" rid="bib30">Sherrard-Smith et al., 2017</xref>). A value of less than one indicates an antagonistic interaction,&#160;=&#160;1 suggests antibodies are acting independently, and greater than one shows synergy.</p><p><supplementary-material id="table1sdata1"><object-id pub-id-type="doi">10.7554/eLife.35213.006</object-id><label>Table 1&#8212;source data 1.</label><caption><title>The raw data used for analysis.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-35213-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Intervention arm</th><th colspan="2" valign="top">Efficacy</th><th colspan="4" valign="top">Synergy</th></tr><tr><th valign="top"/><th valign="top">Reduction in prevalence (95% credible intervals)</th><th valign="top">Reduction in density (95% credible intervals)</th><th valign="top">Prevalence</th><th valign="top">p-value</th><th valign="top">Density</th><th valign="top">p-value</th></tr></thead><tbody><tr><td colspan="7" valign="top">Individual vaccine efficacies</td></tr><tr><td valign="top">&#8195;All TBV combined</td><td valign="top">68.0 (61.1&#8211;74.1)</td><td valign="top">51.5 (6.8&#8211;72.9)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;TBV: MAb-4B7 (50%)</td><td valign="top">33.9 (18.2&#8211;47.4)</td><td valign="top">13.6 (0&#8211;47.5)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;TBV: MAb-4B7 (65%)</td><td valign="top">74.3 (65.7&#8211;82.4)</td><td valign="top">69.3 (47.8&#8211;84.8)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;TBV: MAb-4B7 (85%)</td><td valign="top">95.8 (90.2&#8211;100)</td><td valign="top">94.2 (79.1&#8211;100)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td valign="top">&#8195;PEV: Mab-3D11 (50%)</td><td valign="top">48.0 (36.6&#8211;58.0)</td><td valign="top">2.8 (0&#8211;25.2)</td><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top"/></tr><tr><td colspan="7" valign="top">Combined vaccine efficacies</td></tr><tr><td valign="top">&#8195;PEV and All TBV combined</td><td valign="top">90.8 (86.9&#8211;94.2)</td><td valign="top">90.9 (79.0&#8211;96.4)</td><td valign="top">1.09 (1.02&#8211;1.18)</td><td valign="top">p&lt;0.0035</td><td valign="top">2.08 (1.20&#8211;5.02)</td><td valign="top">p&lt;0.0025</td></tr><tr><td valign="top">&#8195;PEV (50%) and MAb-4B7 (50%)</td><td valign="top">82.2 (74.6&#8211;88.9)</td><td valign="top">85.8 (75.6&#8211;92.8)</td><td valign="top">1.27 (1.07&#8211;1.60)</td><td valign="top">p&lt;0.0015</td><td valign="top">19.04 (1.56&#8211;75.16)</td><td valign="top">p&lt;0.0001</td></tr><tr><td valign="top">&#160;PEV (50%)&#160;and&#160;MAb-4B7&#160;(65%)</td><td valign="top">92.8&#160;(86.1&#160;-&#160;98.6)</td><td valign="top">93.2&#160;(75.4&#160;-&#160;99.7)</td><td valign="top">1.07&#160;(0.98&#160;-&#160;1.17)</td><td valign="top">p&lt;0.0675</td><td valign="top">1.36&#160;(1.02&#160;-&#160;1.97)</td><td valign="top">p&lt;0.02</td></tr><tr><td valign="top">&#8195;PEV (50%) and MAb-4B7 (85%)</td><td valign="top">96.9 (91.2&#160;&#8211;&#160;100)</td><td valign="top">94.8&#160;(74.4&#160;-&#160;100)</td><td valign="top">0.99&#160;(0.93&#160;-&#160;1.04)</td><td valign="top">p&lt;0.5435</td><td valign="top">1.01&#160;(0.78&#160;-&#160;1.22)</td><td valign="top">p&lt;0.3755</td></tr></tbody></table></table-wrap>